A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
| Author | |
|---|---|
| Abstract |
:
Sorafenib has been demonstrated as second-line therapy, with limited significant adverse events at a dose of 400 mg twice a day (b.i.d.) in patients with metastatic renal cell carcinoma. This study evaluated the ability of patients to dose-escalate, response rate, progression-free survival (PFS), and overall survival. |
| Year of Publication |
:
2012
|
| Journal |
:
Clinical genitourinary cancer
|
| Volume |
:
10
|
| Issue |
:
3
|
| Number of Pages |
:
153-8
|
| ISSN Number |
:
1558-7673
|
| URL |
:
https://linkinghub.elsevier.com/retrieve/pii/S1558-7673(12)00052-3
|
| DOI |
:
10.1016/j.clgc.2012.03.001
|
| Short Title |
:
Clin Genitourin Cancer
|
| Download citation |
